[Guide for management of patients with possible respiratory sequelae after a SARS-CoV-2 pneumonia. Support proposals developed by the French-speaking Respiratory Medicine Society. Version of 10 November 2020].

Date publication

novembre 2020

Journal

Revue des maladies respiratoires

Auteurs

Membres identifiés du Cancéropôle Est :
Dr DEBIEUVRE Didier

Tous les auteurs :
Andrejak C, Cottin V, Crestani B, Debieuvre D, Gonzalez-Bermejo J, Morelot-Panzini C, Stach B, Uzunhan Y, Maitre B, Raherison C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/33280941

Résumé

The French-speaking Respiratory Medicine Society (SPLF) proposes a guide for the management of possible respiratory sequelae in patients who have presented with SARS-CoV-2 pneumonia (COVID-19). The proposals are based on known data from previous epidemics, preliminary published data on post COVID-19 follow-up and on expert opinion. The proposals were developed by a group of experts and then submitted, using the Delphi method, to a panel of 22 pulmonologists. Seventeen proposals were validated ranging from additional examinations after the minimum assessment proposed in the SPLF monitoring guide, to inhaled or systemic corticosteroid therapy and antifibrotic agents. These proposals may evolve over time as knowledge accumulates. This guide emphasizes the importance of multidisciplinary discussion.

Mots clés

COVID-19, Fibrose, Fibrosis, Interstitial lung disease, Pneumonia, Pneumonie, Pneumopathie interstitielle diffuse, SARS-CoV-2, Sequelae, Séquelles

Référence

Rev Mal Respir. 2020 Nov 27;: